MK 1006Alternative Names: MK1006
Latest Information Update: 17 Oct 2012
At a glance
- Originator Merck & Co
- Class Antihyperglycaemics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 17 Oct 2012 No development reported - Phase-I for Type-2 diabetes mellitus in Japan (PO)
- 17 Oct 2012 No development reported - Phase-I for Type-2 diabetes mellitus in USA (PO)